Pretransplantation use of the second-generation tyrosine kinase inhibitors has no negative impact on the HCT outcome

Abstract

Pretransplantation therapy with TKI2 in CP CML is safe and reasonable. In BC, the optimal approach before HCT is to reduce the leukemic burden and achieve subsequent CP.